Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
暂无分享,去创建一个
R. Gans | C. Kallenberg | P. D. de Jong | C. Franssen | C. Stegeman | J. Tervaert | S. Hoorntje | S. Hoorntje
[1] R. van Wijk,et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. , 1999, Clinical and experimental rheumatology.
[2] E. Mirapeix,et al. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] C. Kallenberg,et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. , 1999, Journal of the American Society of Nephrology : JASN.
[4] E. Hachulla,et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. , 1999, The American journal of medicine.
[5] J. G. Taylor,et al. Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. , 1999, American journal of clinical pathology.
[6] P. Chapman,et al. The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. , 1999, Kidney international.
[7] C. Kallenberg,et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. , 1998, Journal of the American Society of Nephrology : JASN.
[8] C. Franssen,et al. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti‐proteinase 3 and anti‐myeloperoxidase autoantibodies , 1998, Journal of internal medicine.
[9] G. Hoffman,et al. Antineutrophil cytoplasmic antibodies. , 1998, Bulletin on the rheumatic diseases.
[10] King,et al. T lymphocyte responses to anti‐neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA‐associated systemic vasculitis and persist during disease remission , 1998, Clinical and experimental immunology.
[11] A. Vizjak,et al. Antineutrophil cytoplasmic autoantibodies in atheroembolic disease. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] P Lesavre,et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.
[13] K. Ho,et al. Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration. , 1998, Clinical imaging.
[14] C. Kallenberg,et al. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. , 1998, Kidney international.
[15] C. Michelet,et al. The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? , 1998, Clinical nephrology.
[16] C. Lockwood,et al. Studies of epitope restriction on myeloperoxidase (MPO), an important antigen in systemic vasculitis , 1997, Clinical and experimental immunology.
[17] Dominique,et al. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells. , 1997, Arthritis and rheumatism.
[18] K. De Groot,et al. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). , 1997, Journal of immunological methods.
[19] J. Tervaert,et al. Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. , 1997, Seminars in arthritis and rheumatism.
[20] W. Gross,et al. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. , 1997, The American journal of medicine.
[21] A. Maxwell,et al. Up‐regulation of the endothelial cell adhesion molecule intercellular adhesion molecule‐1 (ICAM‐1) by autoantibodies in autoimmune vasculitis , 1997, Clinical and experimental immunology.
[22] B. Persson,et al. Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? , 1997, Clinical and experimental immunology.
[23] D. Adu,et al. Primary systemic vasculitis , 1997, The Lancet.
[24] A. Devys,et al. Anti‐native and recombinant myeloperoxidase monoclonals and human autoantibodies , 1997, Clinical and experimental immunology.
[25] T. Colby. ANCA defines the clinical disease manifestations of vasculitis. The "con" side of the issue. , 1996, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[26] C. Kallenberg,et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. , 1996, Journal of immunological methods.
[27] J. T. ter Maaten,et al. Respiratory failure in ANCA-associated vasculitis. , 1996, Chest.
[28] A. Mantovani,et al. Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. , 1996, Arthritis and rheumatism.
[29] C. Pusey,et al. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] C. Pusey,et al. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis , 1996, Clinical and experimental immunology.
[31] A. Schwarting,et al. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule‐1 (VCAM‐1) , 1996, Clinical and experimental immunology.
[32] A. Wiik,et al. ANCA antigens: Myeloperoxidase , 1996 .
[33] A. Wiik,et al. ANCA antigens: Proteinase 3 , 1996 .
[34] R. Falk,et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.
[35] J. Kramer,et al. Aphasia, apraxia, and agnosia in the diagnosis of dementia. , 1996, Dementia.
[36] M. Rastaldi,et al. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] J. Feussner,et al. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis , 1995, The Lancet.
[38] I. Bruce,et al. An audit of ANCA in routine clinical practice. , 1995, Postgraduate medical journal.
[39] J. Savige,et al. Epitope mapping of anti‐proteinase 3 and anti‐myeloperoxidase antibodies , 1995, Clinical and experimental immunology.
[40] S. Eriksson,et al. The PiZ gene of α1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis , 1995 .
[41] Y. Sommarin,et al. Characterization of monoclonal antibodies to proteinase-3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. , 1995, Experimental nephrology.
[42] K. Kawasaki,et al. Significance of myeloperoxidase in rapidly progressive glomerulonephritis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] M. Arnaout,et al. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. , 1995, Kidney international.
[44] J. Savige,et al. α1‐Antitrypsin deficiency and anti‐proteinase 3 antibodies in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis , 1995, Clinical and experimental immunology.
[45] C. Pusey,et al. ANCA and predicting relapse in systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.
[46] U. Helmchen,et al. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[47] S. Eriksson,et al. PR3-ANCA-positive vasculitis , 1995 .
[48] R. Gans,et al. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. , 1995, Kidney international.
[49] C. Kallenberg,et al. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG) , 1994, Clinical and experimental immunology.
[50] P. Limburg,et al. Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA): a FcγRII‐dependent process , 1994, Clinical and experimental immunology.
[51] T. Jackson,et al. Invasive amoebiasis is associated with the development of anti‐neutrophil cytoplasmic antibody , 1994, Clinical and experimental immunology.
[52] C. Kallenberg,et al. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. , 1994, Kidney international.
[53] X. Bosch,et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. , 1994, Archives of pathology & laboratory medicine.
[54] D. Underwood,et al. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. , 1994, Journal of immunology.
[55] C. Kallenberg,et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. , 1994, Kidney international.
[56] R J Falk,et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.
[57] C. Kallenberg,et al. Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.
[58] R. Williams,et al. Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. , 1994, Arthritis and rheumatism.
[59] L. Noel,et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. , 1994, The Journal of rheumatology.
[60] R. Falk,et al. Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. , 1994, Advances in experimental medicine and biology.
[61] K. Büschenfelde,et al. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells , 1993, Clinical and experimental immunology.
[62] D. Adu,et al. Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.
[63] R. Goldschmeding,et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy , 1993, The Lancet.
[64] A. Borne,et al. Relevance of classic anti‐neutrophil cytoplasmic autoantibody (C‐ANCA)‐mediated inhibition of proteinase 3‐α1‐antitrypsin complexation to disease activity in Wegener's granulomatosis , 1993, Clinical and experimental immunology.
[65] M. V. van Leeuwen,et al. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. , 1993, Arthritis and rheumatism.
[66] H. Peter,et al. ANCA in diseases other than systemic vasculitis , 1993, Clinical and experimental immunology.
[67] Jean‐Pierre Martin,et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. , 1993, Kidney international.
[68] C. Kallenberg,et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model , 1993, The Journal of experimental medicine.
[69] C. Kallenberg,et al. Serum markers of T cell activation in relapses of Wegener's granulomatosis , 1993, Advances in experimental medicine and biology.
[70] C. Kallenberg,et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases , 1993, Hepatology.
[71] C. Hallahan,et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. , 1993, Arthritis and rheumatism.
[72] D. Chauveau,et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. , 1993, Clinical nephrology.
[73] E. Mark,et al. Correlation of antineutrophil cytoplasmic antibodies with the extrarenal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis. , 1993, Human pathology.
[74] K. Kaneko,et al. Is p-ANCA in ulcerative colitis directed against β-glucuronidase? , 1993, The Lancet.
[75] E. Csernok,et al. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects , 1993, Clinical and experimental immunology.
[76] G. Bodemar,et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. , 1993, Gut.
[77] R. Gans,et al. Clinical features and outcome in patients with glomerulonephritis and antineutrophil cytoplasmic autoantibodies. , 1993, Nephron.
[78] W. Gross,et al. Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). , 1993, Advances in experimental medicine and biology.
[79] E. Bautz,et al. Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. , 1993, Advances in experimental medicine and biology.
[80] I. Caorsi,et al. Antineutrophil-cytoplasmic-autoantibodies in poststreptococcal nephritis. , 1993, Advances in experimental medicine and biology.
[81] G. Gaskin,et al. Disease associations with anti-neutrophil cytoplasmic antibodies. , 1993, Advances in experimental medicine and biology.
[82] A. Borne,et al. Interference of Wegener's granulomatosis autoantibodies with neutrophil Proteinase 3 activity , 1992, Clinical and experimental immunology.
[83] C. Kallenberg,et al. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. , 1992, The American journal of medicine.
[84] M. Keogan,et al. Activation of normal neutrophils by anti‐neutrophil cytoplasm antibodies , 1992, Clinical and experimental immunology.
[85] J. Grünfeld,et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis , 1992, Clinical and experimental immunology.
[86] C. Heesen,et al. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. , 1992, Arthritis and rheumatism.
[87] K. Elkon,et al. Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3. , 1992, Journal of immunology.
[88] R. Terrell,et al. Anti‐myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase , 1992, Clinical and Experimental Immunology.
[89] J. Pearson,et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. , 1992, The American journal of pathology.
[90] H. Kida,et al. Two distinct types of crescentic glomerulonephritis. , 1992, Clinical nephrology.
[91] E. Pettersson,et al. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. , 1992, Clinical nephrology.
[92] M. Kamm,et al. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. , 1992, Gut.
[93] Guy Hoffman,et al. Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.
[94] R. Goldschmeding,et al. Substrate and inhibitor studies on proteinase 3 , 1992, FEBS letters.
[95] R. Falk,et al. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. , 1992, Kidney international.
[96] A. Borne,et al. Anti‐neutrophil cytoplasmic autoantibodies in patients with symptomatic HIV infection , 1992, Clinical and experimental immunology.
[97] K. Andrassy,et al. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. , 1992, Journal of the American Society of Nephrology : JASN.
[98] R. Terrell,et al. Antibodies Against Granule Proteins Activate Neutrophils In Vitro , 1991, Journal of leukocyte biology.
[99] L. Revert,et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. , 1991, Clinical nephrology.
[100] C. Kallenberg,et al. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. , 1991, The American journal of medicine.
[101] P. Gueirard,et al. Anti-myeloperoxidase antibodies: immunological characteristics and clinical associations. , 1991, Journal of autoimmunity.
[102] J. Savige,et al. Detection of anti‐myeloperoxidase and anti‐elastase antibodies in vasculitides and infections , 1991, Clinical and experimental immunology.
[103] R. Wiesner,et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. , 1991, Gastroenterology.
[104] G. Spickett,et al. Aritineutrophil cytoplasmic antibodies, cystic fibrosis, and infection , 1991, The Lancet.
[105] E. Ritz,et al. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. , 1991, Clinical nephrology.
[106] P. Limburg,et al. Predominance of IgGl and IgG4 subclasses of anti‐neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders , 1991, Clinical and experimental immunology.
[107] A. Sjöholm,et al. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment , 1991, Journal of internal medicine.
[108] R. Goldschmeding,et al. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome , 1991, Thorax.
[109] E. Ritz,et al. Clinical significance of the ANCA test for diagnosis of systemic necrotizing vasculitis. , 1991, Contributions to nephrology.
[110] C. Pusey,et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[111] C. Kallenberg,et al. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.
[112] T. Carey,et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.
[113] T. The,et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.
[114] A. Sjöholm,et al. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine‐induced lupus , 1990, Clinical and Experimental Immunology.
[115] S. Targan,et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.
[116] R. Falk,et al. Antineutrophil cytoplasmic autoantibodies and associated diseases: a review. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[117] R J Falk,et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[118] J. Hoidal,et al. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. , 1990, Blood.
[119] R. Gans,et al. Different immunological specificities and disease associations of c-ANCA and p-ANCA. , 1990, The Netherlands journal of medicine.
[120] C. Nathan,et al. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. , 1990, The Journal of clinical investigation.
[121] D. Jayne,et al. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. , 1990, Kidney international.
[122] R. Goldschmeding,et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. , 1990, Kidney international.
[123] J. Lüdemann,et al. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme , 1990, The Journal of experimental medicine.
[124] J. Velosa,et al. Risk factors in idiopathic renal vasculitis and glomerulonephritis. , 1989, Kidney international.
[125] M. Arnaout,et al. Wegener9s granulomatosis autoantigen is a novel neutrophil serine proteinase [see comments] , 1989 .
[126] C. Hack,et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. , 1989, The Journal of clinical investigation.
[127] C. Kallenberg,et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.
[128] R. Falk,et al. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. , 1989, The American journal of pathology.
[129] M. Arnaout,et al. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. , 1989, Blood.
[130] C. Nathan,et al. Antibiotic proteins of human polymorphonuclear leukocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[131] U. Specks,et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. , 1989, Annals of internal medicine.
[132] S. Weiss. Tissue destruction by neutrophils. , 1989, The New England journal of medicine.
[133] J. Hoidal,et al. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. , 1988, The Journal of clinical investigation.
[134] R. Goldschmeding,et al. AUTOANTIBODIES AGAINST MYELOID LYSOSOMAL-ENZYMES - A NOVEL CLASS OF AUTOANTIBODIES ASSOCIATED WITH VASCULITIC SYNDROMES , 1988 .
[135] R. Falk,et al. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.
[136] W. Couser. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[137] J. Neugarten,et al. The existence of a protracted course in crescentic glomerulonephritis. , 1987, Kidney international.
[138] T. H. The,et al. AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.
[139] B. Haynes,et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.
[140] J. E. Moran,et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? , 1982, British medical journal.
[141] H. Kreis,et al. Rapidly progressive glomerulonephritis. A clinical and pathologic study. , 1978, The American journal of medicine.
[142] K. Pryzwansky,et al. Immunocytochemical localization of myeloperoxidase, lactoferrin, lysozyme and neutral proteases in human monocytes and neutrophilic granulocytes. , 1978, Journal of the Reticuloendothelial Society.
[143] J. Schultz,et al. Studies on the chlorinating activity of myeloperoxidase. , 1976, The Journal of biological chemistry.